Linc8986 and linc0597 in plasma are novel biomarkers for systemic lupus erythematosus

Rong,Chunli; Xu,Huafeng; Yan,Changxin; Wei,Feng; Zhou,Haizhou; Guan,Xiuru

doi:10.3892/etm.2021.10644

Linc8986 and linc0597 in plasma are novel biomarkers for systemic lupus erythematosus

Authors:
- Chunli Rong
- Huafeng Xu
- Changxin Yan
- Feng Wei
- Haizhou Zhou
- Xiuru Guan
View Affiliations

Affiliations: Department of Laboratory Diagnosis, The First Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang 150001, P.R. China, Department of Radio‑Immunity, Heilongjiang Provincial Hospital, Harbin, Heilongjiang 150081, P.R. China
Published online on: August 24, 2021 https://doi.org/10.3892/etm.2021.10644
Article Number: 1210
Copyright: © Rong et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Despite increasing evidence that large intergenic non‑coding RNAs (lincRNAs) are widely involved in human disease, the role of lincRNAs in the development of systemic lupus erythematosus (SLE) has remained largely elusive. The purpose of the present study was to investigate the expression of three lincRNAs (linc0597, linc8986 and linc7190) in the plasma of patients with SLE and their potential use as biomarkers for the diagnosis and treatment of SLE. Plasma samples were obtained from 54 patients with SLE, 24 patients with rheumatoid arthritis (RA), 24 patients with Sjogren's syndrome (SS) and 22 healthy controls. LincRNA expression levels were measured by reverse transcription‑quantitative PCR. Compared with those in the healthy controls, the plasma levels of linc0597 and linc8986 were significantly increased in the patients with SLE (P<0.001), while the difference in the level of linc7190 was not significant (P=0.052). In addition, there was no significant difference in the levels of linc0597 and linc8986 among patients with RA, patients with SS and the healthy controls (P>0.05). Compared with patients with SLE without lupus nephritis (LN), the levels of linc0597 were significantly higher in patients with LN (P=0.044). For linc7190 and linc8986, there was no significant difference between patients with and without LN (P>0.05). Furthermore, complement component 3 (C3) levels were used to evaluate whether the expression of linc8986 and linc0597 is related to the activity of SLE. The results indicated that the levels of linc8986 and linc0597 were negatively correlated with the level of C3 (P<0.001 and P=0.004, respectively). Further analysis suggested that linc0597 and linc8986 were able to specifically identify patients with SLE and that a combination of linc0597 and linc8986 may improve the diagnostic accuracy. Therefore, the plasma levels of linc0597 and linc8986 may be suitable biomarkers for diagnosing SLE.

View Figures

View References

1	Herrada AA, Escobedo N, Iruretagoyena M, Valenzuela RA, Burgos PI, Cuitino L and Llanos C: Innate immune cells' contribution to systemic lupus erythematosus. Front Immunol. 10(772)2019.PubMed/NCBI View Article : Google Scholar
2	Luo Q, Li X, Xu C, Zeng L, Ye J, Guo Y, Huang Z and Li J: Integrative analysis of long non-coding RNAs and messenger RNA expression profiles in systemic lupus erythematosus. Mol Med Rep. 17:3489–3496. 2018.PubMed/NCBI View Article : Google Scholar
3	Huang HT, Chen JM, Guo J, Lan Y and Wei YS: The association of interleukin-31 polymorphisms with interleukin-31 serum levels and risk of systemic lupus erythematosus. Rheumatol Int. 36:799–805. 2016.PubMed/NCBI View Article : Google Scholar
4	Wenderfer SE and Eldin KW: Lupus nephritis. Pediatr Clin North Am. 66:87–99. 2019.PubMed/NCBI View Article : Google Scholar
5	Thomas G, Mancini J, Jourde-Chiche N, Sarlon G, Amoura Z, Harlé JR, Jougla E and Chiche L: Mortality associated with systemic lupus erythematosus in france assessed by multiple-cause-of-death analysis. Arthritis Rheumatol. 66:2503–2511. 2014.PubMed/NCBI View Article : Google Scholar
6	Troldborg A, Jensen L, Deleuran B, Stengaard-Pedersen K, Thiel S and Jensenius JC: The C3dg fragment of complement is superior to conventional C3 as a diagnostic biomarker in systemic lupus erythematosus. Front Immunol. 9(581)2018.PubMed/NCBI View Article : Google Scholar
7	Mulvihill E, Ardoin S, Thompson SD, Zhou B, Yu GR, King E, Singer N, Levy DM, Brunner H, Wu YL, et al: Elevated serum complement levels and higher gene copy number of complement C4B are associated with hypertension and effective response to statin therapy in childhood-onset systemic lupus erythematosus (SLE). Lupus Sci Med. 6(e000333)2019.PubMed/NCBI View Article : Google Scholar
8	Qu C, Zhang J, Zhang X, Du J, Su B and Li H: Value of combined detection of anti-nuclear antibody, anti-double-stranded DNA antibody and C3, C4 complements in the clinical diagnosis of systemic lupus erythematosus. Exp Ther Med. 17:1390–1394. 2019.PubMed/NCBI View Article : Google Scholar
9	Lekka E and Hall J: Noncoding RNAs in disease. FEBS Lett. 592:2884–2900. 2018.PubMed/NCBI View Article : Google Scholar
10	Tian J, An X and Niu L: Role of microRNAs in cardiac development and disease. Exp Ther Med. 13:3–8. 2017.PubMed/NCBI View Article : Google Scholar
11	Zhou Q, Yu Q, Gong Y, Liu Z, Xu H, Wang Y and Shi Y: Construction of a lncRNA-miRNA-mRNA network to determine the regulatory roles of lncRNAs in psoriasis. Exp Ther Med. 18:4011–4021. 2019.PubMed/NCBI View Article : Google Scholar
12	Guttman M, Amit I, Garber M, French C, Lin MF, Feldser D, Huarte M, Zuk O, Carey BW, Cassady JP, et al: Chromatin signature reveals over a thousand highly conserved large non-coding RNAs in mammals. Nature. 458:223–227. 2009.PubMed/NCBI View Article : Google Scholar
13	Messemaker TC, Frank-Bertoncelj M, Marques RB, Adriaans A, Bakker AM, Daha N, Gay S, Huizinga TW, Toes REM, Mikkers HMM and Kurreeman F: A novel long non-coding RNA in the rheumatoid arthritis risk locus TRAF1-C5 influences C5 mRNA levels. Genes Immun. 17:85–92. 2015.PubMed/NCBI View Article : Google Scholar
14	Yi R, Yang L, Zeng S and Su Y: Different expression profile of mRNA and long noncoding RNA in autoimmune thyroid diseases patients. J Cell Biochem. 120:19442–19456. 2019.PubMed/NCBI View Article : Google Scholar
15	Wu Y, Zhang F, Ma J, Zhang X, Wu L, Qu B, Xia S, Chen S, Tang Y and Shen N: Association of large intergenic noncoding RNA expression with disease activity and organ damage in systemic lupus erythematosus. Arthritis Res Ther. 17(131)2015.PubMed/NCBI View Article : Google Scholar
16	Zheng CZ, Yan WW, Luo YL, Wang TL and Shu YB: Value of sTNF-R1 and linc0597 as indicators for disease activity and diagnosis of lupus nephritis. Eur Rev Med Pharmacol Sci. 24:5582–5591. 2020.PubMed/NCBI View Article : Google Scholar
17	Wu GC, Li J, Leng RX, Li XP, Li XM, Wang DG, Pan HF and Ye DQ: Identification of long non-coding RNAs GAS5, linc0597 and lnc-DC in plasma as novel biomarkers for systemic lupus erythematosus. Oncotarget. 8:23650–23663. 2017.PubMed/NCBI View Article : Google Scholar
18	Li Z, Chao TC, Chang KY, Lin N, Patil VS, Shimizu C, Head SR, Burns JC and Rana TM: The long noncoding RNA THRIL regulates TNF expression through its interaction with hnRNPL. Proc Natl Acad Sci USA. 111:1002–1007. 2014.PubMed/NCBI View Article : Google Scholar
19	Yuan S, Tang C, Chen D, Li F, Huang M, Ye J, He Z, Li W, Chen Y, Lin X, et al: miR-98 modulates cytokine production from human PBMCs in systemic lupus erythematosus by targeting IL-6 mRNA. J Immunol Res. 2019(9827574)2019.PubMed/NCBI View Article : Google Scholar
20	Hochberg MC: Updating the American college of rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 40(1725)1997.PubMed/NCBI View Article : Google Scholar
21	Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO III, Birnbaum NS, Burmester GR, Bykerk VP, Cohen MD, et al: 2010 rheumatoid arthritis classification criteria: An American college of Rheumatology/European league against rheumatism collaborative initiative. Arthritis Rheum. 69:1580–1588. 2010.PubMed/NCBI View Article : Google Scholar
22	Vitali C, Bombardieri S, Jonsson R, Moutsopoulos HM, Alexander EL, Carsons SE, Daniels TE, Fox PC, Fox RI, Kassan SS, et al: Classification criteria for sjögren's syndrome: A revised version of the European criteria proposed by the American-European consensus group. Ann Rheum Dis. 61:554–558. 2002.PubMed/NCBI View Article : Google Scholar
23	Tong YS, Wang XW, Zhou XL, Liu ZH, Yang TX, Shi WH, Xie HW, Lv J, Wu QQ and Cao XF: Identification of the long non-coding RNA POU3F3 in plasma as a novel biomarker for diagnosis of esophageal squamous cell carcinoma. Mol Cancer. 14(3)2015.PubMed/NCBI View Article : Google Scholar
24	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.PubMed/NCBI View Article : Google Scholar
25	Zhao CN, Mao YM, Liu LN, Li XM, Wang DG and Pan HF: Emerging role of lncRNAs in systemic lupus erythematosus. Biomed Pharmacother. 106:584–592. 2018.PubMed/NCBI View Article : Google Scholar
26	Wu GC, Hu Y, Guan SY, Ye DQ and Pan HF: Differential plasma expression profiles of long non-Coding RNAs reveal potential biomarkers for systemic lupus erythematosus. Biomolecules. 9(206)2019.PubMed/NCBI View Article : Google Scholar
27	Song X, Rui C, Meng L, Zhang R, Shen R, Ding H, Li J, Li J and Long W: Long non-coding RNA RPAIN regulates the invasion and apoptosis of trophoblast cell lines via complement protein C1q. Oncotarget. 8:7637–7646. 2017.PubMed/NCBI View Article : Google Scholar
28	Zhang Q, Liang Y, Yuan H, Li S, Wang JB, Li XM, Tao JH, Pan HF and Ye DQ: Integrated analysis of lncRNA, miRNA and mRNA expression profiling in patients with systemic lupus erythematosus. Arch Med Sci. 15:872–879. 2019.PubMed/NCBI View Article : Google Scholar
29	Müller N, Döring F, Klapper M, Neumann K, Schulte DM, Türk K, Schröder JO, Zeuner RA, Freitag-Wolf S, Schreiber S and Laudes M: Interleukin-6 and tumour necrosis factor-α differentially regulate lincRNA transcripts in cells of the innate immune system in vivo in human subjects with rheumatoid arthritis. Cytokine. 68:65–68. 2014.PubMed/NCBI View Article : Google Scholar
30	Ren S, Wang F, Shen J, Sun Y, Xu W, Lu J, Wei M, Xu C, Wu C, Zhang Z, et al: Long non-coding RNA metastasis associated in lung adenocarcinoma transcript 1 derived miniRNA as a novel plasma-based biomarker for diagnosing prostate cancer. Eur J Cancer. 49:2949–2959. 2013.PubMed/NCBI View Article : Google Scholar
31	Cabili MN, Trapnell C, Goff L, Koziol M, Tazon-Vega B, Regev A and Rinn JL: Integrative annotation of human large intergenic noncoding RNAs reveals global properties and specific subclasses. Genes Dev. 25:1915–1927. 2011.PubMed/NCBI View Article : Google Scholar
32	Kawai T and Akira S: The role of pattern-recognition receptors in innate immunity: Update on toll-like receptors. Nat Immunol. 11:373–384. 2010.PubMed/NCBI View Article : Google Scholar
33	Blasius AL and Beutler B: Intracellular toll-like receptors. Immunity. 32:305–315. 2010.PubMed/NCBI View Article : Google Scholar
34	Cansu DÜ, Temiz G, Açıkalın MF and Korkmaz C: Pauci-immune lupus nephritis: Possibility or co-incidence? Eur J Rheumatol. 4:73–75. 2017.PubMed/NCBI View Article : Google Scholar
35	Haładyj E and Cervera R: Do we still need renal biopsy in lupus nephritis? Reumatologia. 54:61–66. 2016.PubMed/NCBI View Article : Google Scholar
36	Chaichian Y, Wallace DJ and Weisman MH: A promising approach to targeting type 1 IFN in systemic lupus erythematosus. J Clin Invest. 129:958–961. 2019.PubMed/NCBI View Article : Google Scholar
37	Murayama G, Furusawa N, Chiba A, Yamaji K, Tamura N and Miyake S: Enhanced IFN-α production is associated with increased TLR7 retention in the lysosomes of palasmacytoid dendritic cells in systemic lupus erythematosus. Arthritis Res Ther. 19(234)2017.PubMed/NCBI View Article : Google Scholar
38	Higgs BW, Liu Z, White B, Zhu W, White WI, Morehouse C, Brohawn P, Kiener PA, Richman L, Fiorentino D, et al: Patients with systemic lupus erythematosus, myositis, rheumatoid arthritis and scleroderma share activation of a common type I interferon pathway. Ann Rheum Dis. 70:2029–2036. 2011.PubMed/NCBI View Article : Google Scholar
39	Bodewes ILA, Huijser E, van Helden-Meeuwsen CG, Tas L, Huizinga R, Dalm V, van Hagen PM, Groot N, Kamphuis S, van Daele PLA and Versnel MA: TBK1: A key regulator and potential treatment target for interferon positive sjögren's syndrome, systemic lupus erythematosus and systemic sclerosis. J Autoimmun. 91:97–102. 2018.PubMed/NCBI View Article : Google Scholar
40	Luo Q, Xu C, Li X, Zeng L, Ye J, Guo Y, Huang Z and Li J: Comprehensive analysis of long non-coding RNA and mRNA expression profiles in rheumatoid arthritis. Exp Ther Med. 14:5965–5973. 2017.PubMed/NCBI View Article : Google Scholar